| P/E (FY) | — | Sales (TTM) | $4.44B |
| Earnings (TTM) | $29.5M | ROE | −8.47% |
| Net Margin | −8.35% | ROIC | −4.23% |
| Debt / Equity | 1.24 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 5.26% |
Jazz Pharmaceuticals identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. Its marketed medicines include Xywav for narcolepsy-related cataplexy and excessive daytime sleepiness and idiopathic hypersomnia, Epidiolex for certain seizure disorders, Rylaze and Enrylaze for acute lymphoblastic leukemia and lymphoblastic lymphoma, Zepzelca for small cell lung cancer, Ziihera, Modeyso, and Defitelio.
| Market Cap | $16.12B | Trading Days | 4816 |
| 52W High | 261.30 |
| 52W Low | 105.00 |
| % Off High | −1.67% |
| YTD | 51.13% | 1Y | 118.88% |
| 3Y | 96.33% | 5Y | 47.20% |
| 10Y | 68.12% | Since incept. (ann.) | 14.98% |
US 90% · Europe 8% · Other Countries 2%
| Ann. Volatility (1Y) | 37.55% | Ann. Volatility (3Y) | 33.36% |
| Sharpe (1Y) | 2.30 | Sharpe (3Y) | 0.85 |
| Max Drawdown (1Y) | −11.42% | Max Drawdown (3Y) | −32.71% |
| Beta (3Y, vs SPY) | 0.30 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| BBIO | BridgeBio Pharma, Inc. | $16.76B | — |
| QNRX | Quoin Pharmaceuticals, Ltd. | $14.09B | — |
| ELAN | Elanco Animal Health Inc | $12.75B | — |
| ZLAB | Zai Lab Ltd | $20.39B | — |
| VTRS | Viatris Inc | $20.80B | — |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $12.42B | — |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $12.08B | — |
| AXSM | Axsome Therapeutics, Inc. | $12.05B | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $12.00B | 34.5 |
| UTHR | UNITED THERAPEUTICS Corp | $22.23B | 18.8 |
| INSM | INSMED Inc | $22.57B |
| ROIV | Roivant Sciences Ltd. | $24.34B | — |
